Accession Number:

ADA386742

Title:

Treatment of Metastatic Breast Carcinoma Refactory to Doxorubicin with Liposomal-Annamycin

Descriptive Note:

Annual rept. 23 Sep 1998-22 Sep 1999

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

1999-10-01

Pagination or Media Count:

7.0

Abstract:

Fourteen patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 25 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50 of patients. No antitumor responses were seen.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE